Antibody drug discovery platform combining phage antibody libraries, the ICOS method and other technologies
First written in FY2021. 9 of 16 entries say "Restated". Latest entry: 2026-09-14.
No other company in this theme has enough history to compare yet.
- FY2025AdvancedAnnual report
「During the current fiscal year, the company successfully created PPMX Antibody Library 2, an improved version of its phage library. Using this library, the company will develop its database and use its proprietary AI drug-discovery technology to acquire antibodies against challenging antigens that are difficult to target.」
In addition to our conventional antibody-generation platform, we are addressing challenging antigens using an improved phage library and AI drug discovery. - FY2025-H1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our antibody generation platform.」
Reaffirming our drug discovery platform based on an antibody-generation platform. - FY2024AdvancedAnnual report
「We have also begun using single B-cell screening (Note 7) as a new antibody-generation technology.」
In addition to conventional phage display and hybridoma methods, we began using single B-cell screening, thereby expanding our antibody-generation platform. - FY2024-Q1RestatedAnnual report
「We are advancing antibody development, primarily in the oncology field, by leveraging our efficient antibody generation platform.」
Reaffirming the antibody drug discovery platform built around an efficient antibody-generation platform. - FY2023RestatedAnnual report
「We conduct basic research, preclinical development and clinical development of therapeutic antibodies for cancer and other diseases by fully exploiting antibody screening technology using our proprietary phage antibody library and antibody technologies, including transcriptome databases and antigen expression technology.」
The company has reaffirmed its drug discovery platform combining its proprietary phage antibody library, screening technology, transcriptome technology and antigen expression technology. - FY2023-Q3RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained from the company's proprietary phage library using ICOS, the company's patented screening technology.」
The company has reaffirmed PPMX-T003's antibody-generation platform using its proprietary phage library and patented ICOS method. - FY2023-Q2RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained from the company's proprietary phage library using ICOS, the company's patented screening technology.」
The company has reaffirmed PPMX-T003's antibody-generation platform using its proprietary phage library and patented ICOS method. - FY2023-Q1RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained from the company's proprietary phage library using ICOS, the company's patented screening technology.」
The company has reaffirmed the antibody-generation platform using its proprietary phage library and patented ICOS method in its description of PPMX-T003's development. - FY2022-Q3RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained from the company's proprietary phage library using ICOS, a screening technology patented by the company, through phage display.」
The company has reaffirmed the antibody-generation platform using its proprietary phage library, the ICOS method and phage display. - FY2022-Q2RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained through phage display using the company's proprietary phage library and ICOS method, its proprietary screening technology. It targets the transferrin receptor (TfR).」
The company has reaffirmed the antibody-generation platform using its proprietary phage library, the ICOS method and phage display. - FY2022-Q1RestatedAnnual report
「PPMX-T003 is a unique fully human antibody obtained through phage display using the company's proprietary phage library and ICOS method, its proprietary screening technology. It targets the transferrin receptor (TfR).」
The company has reaffirmed the antibody-generation platform using its proprietary phage library, the ICOS method and phage display. - FY2021First statedAnnual report
「Our technology combines these two antibody technologies with seed discovery techniques to obtain antibody drug candidates suited to medical needs.」
The company describes a technology platform combining the hybridoma method, phage display, proprietary screening and target discovery.